Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, Scaglione GL, Arcangeli V, De Cecio R, Scognamiglio G, Greco F, Spina A, Turinetto M, Russo D, Carbone V, Casartelli C, Schettino C, Perrone F. Pignata S, et al. Among authors: turinetto m. Ann Oncol. 2024 Jul;35(7):667-676. doi: 10.1016/j.annonc.2024.04.007. Epub 2024 May 3. Ann Oncol. 2024. PMID: 38704093 Clinical Trial.
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.
Giannone G, Castaldo D, Tuninetti V, Scotto G, Turinetto M, Valsecchi AA, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Giannone G, et al. Among authors: turinetto m. Front Oncol. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008. eCollection 2022. Front Oncol. 2022. PMID: 35692798 Free PMC article.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Musacchio L, Turinetto M, Arenare L, Bartoletti M, Califano D, Tuninetti V, Marchetti C, Cormio G, Loizzi V, Pisano C, Salutari V, Valabrega G, Priolo D, Cecere SC, Ventriglia J, Raspagliesi F, Perrone F, Fagotti A, Lorusso D, Scambia G, Pignata S. Musacchio L, et al. Among authors: turinetto m. Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23. Gynecol Oncol. 2023. PMID: 36965291
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: turinetto m. Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023. Front Oncol. 2023. PMID: 37781174 Free PMC article.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: turinetto m. Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023. Front Oncol. 2024. PMID: 38318323 Free PMC article.
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Giannone G, Scotto G, Katsaros D, De Giorgi U, Farolfi A, Borella F, Cosma S, Ferrero A, Mangiacotti S, Villa M, Tuninetti V, Ghisoni E, Turinetto M, Mittica G, Gemmiti S, Zavallone L, Aglietta M, Pasini B, Di Maio M, Valabrega G. Giannone G, et al. Among authors: turinetto m. Gynecol Oncol. 2021 Jul;162(1):80-87. doi: 10.1016/j.ygyno.2021.04.018. Epub 2021 Apr 22. Gynecol Oncol. 2021. PMID: 33896588 Free article.
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Milani A, Tuninetti V, Pignata S, Lorusso D, Castaldo D, De Giorgi U, Savarese A, Biglia N, Scandurra G, Mangili G, Di Maio M, Turinetto M, Bellero M, Mammoliti S, Testa S, Scotto G, Purro A, Artioli G, Valabrega G. Milani A, et al. Among authors: turinetto m. Tumori. 2023 Oct;109(5):490-495. doi: 10.1177/03008916221146820. Epub 2023 Jan 6. Tumori. 2023. PMID: 36609207
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, Malaguti P, Baldoni A, Scollo P, Scandurra G, Parisi A, Artioli G, Palaia I, Vertechy L, Bergamini A, Picardo E, Tuninetti V, Scotto G, Scambia G, Pignata S, Valabrega G. Turinetto M, et al. Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041. Cancers (Basel). 2023. PMID: 38201470 Free PMC article.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, Valabrega G. Tuninetti V, et al. Among authors: turinetto m. Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032. Cancers (Basel). 2023. PMID: 36831376 Free PMC article.
28 results